Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sarah Bergamin"'
Autor:
Benita C. Y. Tse, Sarah Bergamin, Pascal Steffen, George Hruby, Nick Pavlakis, Stephen J. Clarke, Justin Evans, Alexander Engel, Andrew Kneebone, Mark P. Molloy
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTApproximately 20% of locally advanced rectal cancer (LARC) patients treated preoperatively with chemoradiotherapy (CRT) achieve pathologically confirmed complete regression. However, there are no clinically implemented biomarkers measurable i
Externí odkaz:
https://doaj.org/article/aea7f6541cdc485c9d1d4ad90d20e7ae
Autor:
Alannah Kejda, Alexandra Quinn, Shelley Wong, Toby Lowe, Isabelle Fent, Maegan Gargett, Stephanie Roderick, Kylie Grimberg, Sarah Bergamin, Thomas Eade, Jeremy Booth
Publikováno v:
Physics and Imaging in Radiation Oncology, Vol 28, Iss , Pp 100490- (2023)
Background and purpose: Simulation-free radiotherapy, where diagnostic imaging is used for treatment planning, improves accessibility of radiotherapy for eligible palliative patients. Combining this pathway with online adaptive radiotherapy (oART) ma
Externí odkaz:
https://doaj.org/article/57a4641757f14fb18e1ca5500c42ea3f
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 13, Iss , Pp 38-43 (2018)
Background and purpose: Malignant pleural mesothelioma (MPM) is an aggressive cancer with a propensity for seeding procedure tracts, leading to symptomatic metastases. There is conflicting evidence on the value of prophylactic procedure tract radioth
Externí odkaz:
https://doaj.org/article/3f1e6c654c1f466c8d7ba237f530ea68
Autor:
Thilo, Schuler, Shelley, Wong, Sarah, Bergamin, George, Hruby, Michael, Back, Stephanie, Roderick, Thomas, Eade
Publikováno v:
International journal of radiation oncology, biology, physics. 112(1)
Autor:
Thilo Schuler, Shelley Wong, Sarah Bergamin, George Hruby, Michael Back, Stephanie Roderick, Thomas Eade
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 112:260-261
Autor:
Andrew Kneebone, Kathryn Szymura, Carol Kwong, Julia Hunter, Sarah Bergamin, George Hruby, Andrew Le, Thomas Eade, Jeremy T. Booth, Chris Brown, Geoffrey Schembri, Edward C. Hsiao
Publikováno v:
International journal of radiation oncology, biology, physics. 108(5)
Purpose To report the feasibility, toxicity, and preliminary outcomes (metabolic and biochemical) of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)–directed focal prostate reirradiation usin
Autor:
Emma Gibbs, George Hruby, Matthew Wong, Stephen Clarke, Connie I. Diakos, Malinda Itchins, Sia Kim, Terence C. Chua, J. Rabindran, Anubhav Mittal, Richard Maher, Jennifer Arena, Christopher B. Nahm, Jaswinder S. Samra, Anthony J. Gill, Nick Pavlakis, Sarah Bergamin, Andrew Kneebone
Publikováno v:
European Journal of Surgical Oncology. 43:1711-1717
Background Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease. Neoadjuvant therapy (NA) with chemotherapy (NAC) and radiotherapy (RT) prior to surgery provides promise. In the absence of prospective data, well annotated clinical data from hi
Autor:
Sarah Bergamin, Andrew Kneebone
Publikováno v:
European Urology. 77:699-700
Autor:
Andrew Kneebone, James G. Kench, Sarah Bergamin, J.-F. Biset, George Hruby, Thomas Eade, Paul Sved
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 31(2)
Aims Ductal adenocarcinoma is a rare variant of prostate cancer, and as such clinical outcomes and best management are not well defined. This series demonstrates the atypical presentation and unusual clinical behaviour of ductal adenocarcinoma and pr
Autor:
Nahm Christopher, Sia Kim, Matthew Wong, Geoffrey Schembri, Jaswinder S. Samra, Stephen Clarke, Emma Gibbs, George Hruby, Jennifer Arena, Malinda Itchins, Anthony J. Gill, Sarah Bergamin, Anubhav Mittal, Elizabeth Bailey, Andrew Kneebone, Joel Rabindran, Richard Maher, Nick Pavlakis
Publikováno v:
Journal of Clinical Oncology. 35:395-395
395 Background: The 5 year (yr) overall survival (OS) of pancreas cancer (PC) is < 5%. Surgical resection is the only curative treatment (tx), most relapse within 2yrs. Neoadjuvant (NA) tx can benefit by eradicating micro-metastases, avoids futile su